Literature DB >> 8016894

Tyrosine kinase pathways and the regulation of smooth muscle contractility.

M D Hollenberg1.   

Abstract

Epidermal growth factor (EGF) mediates three tyrosine kinase-dependent smooth muscle response paradigms, two of which comprise a rapid increase in muscle tension and one of which is characterized by an agonist-mediated reduction in sensitivity to other agents. The three types of response are mediated via distinct signal transduction pathways, and marked tissue and species variation have been observed, even for a single growth factor agonist. Vasoactive agents, such as angiotensin II and vasopressin, that act via G protein-coupled receptors can also work via tyrosine kinase pathways to cause contraction in some of the same intact smooth muscle preparations that contract in response to EGF. In this review, Morley Hollenberg discusses the tyrosine kinase-modulated signal transduction pathways for EGF and also agonists that act via G protein-coupled receptors, and hypothesizes that there may be an intermediary non-receptor tyrosine kinase that may serve as a point of convergence for the contractile actions of these agents in smooth muscle.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8016894     DOI: 10.1016/0165-6147(94)90046-9

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  24 in total

Review 1.  A role for the Ca(2+)-dependent tyrosine kinase Pyk2 in tonic depolarization-induced vascular smooth muscle contraction.

Authors:  Ryan D Mills; Mitsuo Mita; Michael P Walsh
Journal:  J Muscle Res Cell Motil       Date:  2015-07-07       Impact factor: 2.698

2.  Nociceptin inhibits T-type Ca2+ channel current in rat sensory neurons by a G-protein-independent mechanism.

Authors:  F A Abdulla; P A Smith
Journal:  J Neurosci       Date:  1997-11-15       Impact factor: 6.167

3.  Proteinase-activated receptors 1 and 2 and the regulation of porcine coronary artery contractility: a role for distinct tyrosine kinase pathways.

Authors:  Mahmoud El-Daly; Mahmoud Saifeddine; Koichiro Mihara; Rithwik Ramachandran; Christopher R Triggle; Morley D Hollenberg
Journal:  Br J Pharmacol       Date:  2014-05       Impact factor: 8.739

Review 4.  Angiotensin II-mediated signal transduction pathways.

Authors:  Yuji Saito; Bradford C Berk
Journal:  Curr Hypertens Rep       Date:  2002-04       Impact factor: 5.369

5.  Agents that increase tyrosine phosphorylation activate a non-selective cation current in single rabbit portal vein smooth muscle cells.

Authors:  A P Albert; A S Aromolaran; W A Large
Journal:  J Physiol       Date:  2001-01-15       Impact factor: 5.182

6.  Differential action of a protein tyrosine kinase inhibitor, genistein, on the positive inotropic effect of endothelin-1 and norepinephrine in canine ventricular myocardium.

Authors:  Li Chu; Jian-Xin Zhang; Ikuo Norota; Masao Endoh
Journal:  Br J Pharmacol       Date:  2005-02       Impact factor: 8.739

7.  A redox-based mechanism for the contractile and relaxing effects of NO in the guinea-pig gall bladder.

Authors:  S Alcón; S Morales; P J Camello; J M Hemming; L Jennings; G M Mawe; M J Pozo
Journal:  J Physiol       Date:  2001-05-01       Impact factor: 5.182

Review 8.  Protein tyrosine phosphorylation in cardiovascular system.

Authors:  A K Srivastava
Journal:  Mol Cell Biochem       Date:  1995 Aug-Sep       Impact factor: 3.396

9.  Mechanism of action of angiotensin II in human isolated subcutaneous resistance arteries.

Authors:  R S Garcha; P S Sever; A D Hughes
Journal:  Br J Pharmacol       Date:  2001-09       Impact factor: 8.739

10.  Mechanisms underlying lysophosphatidylcholine-induced potentiation of vascular contractions in the Otsuka Long-Evans Tokushima Fatty (OLETF) rat aorta.

Authors:  T Matsumoto; T Kobayashi; K Kamata
Journal:  Br J Pharmacol       Date:  2006-10-09       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.